Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension

T Saji; Y Ozawa; T Ishikita; H Matsuura; N Matsuo

doi:10.1016/s0002-9149(96)90408-7

Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension

Am J Cardiol. 1996 Jul 15;78(2):244-7. doi: 10.1016/s0002-9149(96)90408-7.

Authors

T Saji¹, Y Ozawa, T Ishikita, H Matsuura, N Matsuo

Affiliation

¹ Department of Pediatrics, Toho University, Tokyo, Japan.

PMID: 8712155
DOI: 10.1016/s0002-9149(96)90408-7

Abstract

In 4 patients with primary pulmonary hypertension, there was a -24% +/- 20% decrease in pulmonary vascular resistance, a significant increase of cardiac index by +27 +/- 14% in all 4 patients; a -15 +/- 12% decrease in pulmonary artery pressure in 3 patients; and in 3 patients with 12% secondary pulmonary hypertension, there was a -24 +/- 14% decrease in pulmonary vascular resistance. Beraprost appears to be effective as a new pulmonary vasodilative agent.

MeSH terms

Adult
Child
Epoprostenol / analogs & derivatives*
Epoprostenol / pharmacology
Epoprostenol / therapeutic use
Female
Hemodynamics / drug effects*
Humans
Hypertension, Pulmonary / drug therapy
Hypertension, Pulmonary / physiopathology*
Infant
Male
Middle Aged
Platelet Aggregation Inhibitors / pharmacology*
Platelet Aggregation Inhibitors / therapeutic use
Treatment Outcome
Vasodilator Agents / pharmacology*
Vasodilator Agents / therapeutic use

Substances

Platelet Aggregation Inhibitors
Vasodilator Agents
beraprost
Epoprostenol